{"uri": "eng-9414238", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Research_and_development", "type": "wiki", "score": 100, "label": {"eng": "Research and development"}}, {"uri": "http://en.wikipedia.org/wiki/Pipeline_transport", "type": "wiki", "score": 98, "label": {"eng": "Pipeline transport"}}, {"uri": "http://en.wikipedia.org/wiki/Oncology", "type": "wiki", "score": 82, "label": {"eng": "Oncology"}}, {"uri": "http://en.wikipedia.org/wiki/Fiscal_year", "type": "wiki", "score": 79, "label": {"eng": "Fiscal year"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 77, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/BioNTech", "type": "wiki", "score": 73, "label": {"eng": "BioNTech"}}, {"uri": "http://en.wikipedia.org/wiki/COVID-19_vaccine", "type": "wiki", "score": 73, "label": {"eng": "COVID-19 vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Pfizer", "type": "wiki", "score": 73, "label": {"eng": "Pfizer"}}, {"uri": "http://en.wikipedia.org/wiki/Immunotherapy", "type": "wiki", "score": 73, "label": {"eng": "Immunotherapy"}}, {"uri": "http://en.wikipedia.org/wiki/Income_tax", "type": "wiki", "score": 73, "label": {"eng": "Income tax"}}, {"uri": "http://en.wikipedia.org/wiki/Vaccine", "type": "wiki", "score": 73, "label": {"eng": "Vaccine"}}, {"uri": "http://en.wikipedia.org/wiki/Net_income", "type": "wiki", "score": 73, "label": {"eng": "Net income"}}, {"uri": "http://en.wikipedia.org/wiki/Cancer", "type": "wiki", "score": 73, "label": {"eng": "Cancer"}}, {"uri": "http://en.wikipedia.org/wiki/Earnings_per_share", "type": "wiki", "score": 73, "label": {"eng": "Earnings per share"}}, {"uri": "http://en.wikipedia.org/wiki/Common_stock", "type": "wiki", "score": 72, "label": {"eng": "Common stock"}}, {"uri": "http://en.wikipedia.org/wiki/Cost_of_goods_sold", "type": "wiki", "score": 69, "label": {"eng": "Cost of goods sold"}}, {"uri": "http://en.wikipedia.org/wiki/Cash_and_cash_equivalents", "type": "wiki", "score": 69, "label": {"eng": "Cash and cash equivalents"}}, {"uri": "http://en.wikipedia.org/wiki/Welfare", "type": "wiki", "score": 69, "label": {"eng": "Welfare"}}, {"uri": "http://en.wikipedia.org/wiki/Chief_executive_officer", "type": "wiki", "score": 65, "label": {"eng": "Chief executive officer"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 61, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Genmab", "type": "org", "score": 55, "label": {"eng": "Genmab"}}, {"uri": "http://en.wikipedia.org/wiki/GlobeNewswire", "type": "org", "score": 49, "label": {"eng": "GlobeNewswire"}}, {"uri": "http://en.wikipedia.org/wiki/Deutsche_Bundesbank", "type": "org", "score": 47, "label": {"eng": "Deutsche Bundesbank"}}, {"uri": "http://en.wikipedia.org/wiki/Genentech", "type": "org", "score": 44, "label": {"eng": "Genentech"}}, {"uri": "http://en.wikipedia.org/wiki/Mainz", "type": "loc", "score": 44, "label": {"eng": "Mainz"}, "location": {"type": "place", "label": {"eng": "Mainz"}, "country": {"type": "country", "label": {"eng": "Germany"}}}}, {"uri": "http://en.wikipedia.org/wiki/United_States", "type": "loc", "score": 36, "label": {"eng": "United States"}, "location": {"type": "country", "label": {"eng": "United States"}}}, {"uri": "http://en.wikipedia.org/wiki/Idar-Oberstein", "type": "loc", "score": 33, "label": {"eng": "Idar-Oberstein"}, "location": {"type": "place", "label": {"eng": "Idar-Oberstein"}, "country": {"type": "country", "label": {"eng": "Germany"}}}}, {"uri": "http://en.wikipedia.org/wiki/Singapore", "type": "loc", "score": 29, "label": {"eng": "Singapore"}, "location": {"type": "country", "label": {"eng": "Singapore"}}}, {"uri": "http://en.wikipedia.org/wiki/Germany", "type": "loc", "score": 29, "label": {"eng": "Germany"}, "location": {"type": "country", "label": {"eng": "Germany"}}}, {"uri": "http://en.wikipedia.org/wiki/China", "type": "loc", "score": 29, "label": {"eng": "China"}, "location": {"type": "country", "label": {"eng": "China"}}}, {"uri": "http://en.wikipedia.org/wiki/S&P_Global", "type": "org", "score": 25, "label": {"eng": "S&P Global"}}, {"uri": "http://en.wikipedia.org/wiki/South_Africa", "type": "loc", "score": 25, "label": {"eng": "South Africa"}, "location": {"type": "country", "label": {"eng": "South Africa"}}}, {"uri": "http://en.wikipedia.org/wiki/Australia", "type": "loc", "score": 25, "label": {"eng": "Australia"}, "location": {"type": "country", "label": {"eng": "Australia"}}}, {"uri": "http://en.wikipedia.org/wiki/Asia", "type": "loc", "score": 22, "label": {"eng": "Asia"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Africa", "type": "loc", "score": 22, "label": {"eng": "Africa"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/North_America", "type": "loc", "score": 22, "label": {"eng": "North America"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Suzhou", "type": "loc", "score": 22, "label": {"eng": "Suzhou"}, "location": {"type": "place", "label": {"eng": "Suzhou"}, "country": {"type": "country", "label": {"eng": "China"}}}}, {"uri": "http://en.wikipedia.org/wiki/Europe", "type": "loc", "score": 18, "label": {"eng": "Europe"}, "location": null}, {"uri": "http://en.wikipedia.org/wiki/Regeneron_Pharmaceuticals", "type": "org", "score": 15, "label": {"eng": "Regeneron Pharmaceuticals"}}, {"uri": "http://en.wikipedia.org/wiki/United_Nations", "type": "org", "score": 15, "label": {"eng": "United Nations"}}, {"uri": "http://en.wikipedia.org/wiki/Kigali", "type": "loc", "score": 15, "label": {"eng": "Kigali"}, "location": {"type": "place", "label": {"eng": "Kigali"}, "country": {"type": "country", "label": {"eng": "Rwanda"}}}}, {"uri": "http://en.wikipedia.org/wiki/Marburg", "type": "loc", "score": 11, "label": {"eng": "Marburg"}, "location": {"type": "place", "label": {"eng": "Marburg"}, "country": {"type": "country", "label": {"eng": "Germany"}}}}], "eventDate": "2024-03-20", "totalArticleCount": 7, "title": {"eng": "Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results"}, "summary": {"eng": "Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody\n\nEntered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties\n\nStrengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering\n\nVANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the"}, "location": {"type": "place", "label": {"eng": "Mainz"}, "country": {"type": "country", "label": {"eng": "Germany"}}}, "categories": [{"uri": "dmoz/Business/Biotechnology_and_Pharmaceuticals", "label": "dmoz/Business/Biotechnology and Pharmaceuticals", "wgt": 67}, {"uri": "dmoz/Society/Issues/Business", "label": "dmoz/Society/Issues/Business", "wgt": 100}, {"uri": "dmoz/Society/Issues/Health", "label": "dmoz/Society/Issues/Health", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 87}], "articleCounts": {"eng": 7}, "sentiment": 0.3019607843137255, "wgt": 448588800, "relevance": 1}